Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma.pdf (278.39 kB)
Download fileInefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma
Key Points:
• Optimal use of phase II data may reduce chances of failure in subsequent phase III
studies.
• Inappropriate utilization or a lack of phase II data appears to contribute to phase III failure.
• Only 35% of phase III trials in our review transitioned from phase II to III in an optimal
manner.